Comparison of FDG and FAPI in Patients With Various Types of Cancer

NCT04416165 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital of Xiamen University

Phase

Not applicable

Started

2019-10-20

Last updated

2023-08-08

Condition(s) studied

Tumor, SolidPositron-Emission TomographyMetastasis

Investigational drug(s) / intervention(s)

18F-FDG and 68Ga-DOTA-FAPI -04 PET/CT

18F-FDG and 68Ga-DOTA-FAPI -04 PET/CT: Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.

Study summary

To evaluate the potential usefulness of 68Ga-DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 18F-FDG PET/CT.

Eligibility

Sex

ALL

Min age

18 Years

Max age

90 Years

Healthy volunteers

Inclusion Criteria: * (i) adult patients (aged 18 years or order); (ii) patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report); (iii) patients who had scheduled both 18F-FDG and 68Ga-DOTA-FAPI-04 PET/CT scans; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: * (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Primary outcome measure(s)

SUV — 30 days
Standardized uptake value (SUV) of 18F/ 68Ga-DOTA-FAPI-04 for each target lesion of subject or suspected primary tumor or/and metastasis.

Trial sites (1)

Facility	City	Region	Status
First affiliated hospital of xiamen university	Xiamen	Fujian	Recruiting

More The First Affiliated Hospital of Xiamen University trials in China

The Effect of Semaglutide on Bone Health Starting soon

Ultrasound Assessment of Fetal Growth Parameters Enrolling by invitation

Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC Recruiting

PET/CT for Trop2 ADC Response Evaluation NSCLC Recruiting

Application of Augmented Reality Neuronavigation in Transnasal Endoscopic Skull Base Surgery Recruiting

Other trials for the same condition

Somatostatin Receptor PET/CT in SSTR-Related Disease Patients Recruiting

A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC Recruiting

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor Recruiting

NW-301 TCR-T in Patients With Advanced Solid Tumor Starting soon

Integrative Analysis of CRC Liver Metastasis Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04416165 on ClinicalTrials.gov ↗ ← All trials in China